miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases t...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253118302518 |
_version_ | 1818261001050521600 |
---|---|
author | Arulraj Nadaradjane Joséphine Briand Gwenola Bougras-Cartron Valentine Disdero François M. Vallette Jean-Sébastien Frenel Pierre-François Cartron |
author_facet | Arulraj Nadaradjane Joséphine Briand Gwenola Bougras-Cartron Valentine Disdero François M. Vallette Jean-Sébastien Frenel Pierre-François Cartron |
author_sort | Arulraj Nadaradjane |
collection | DOAJ |
description | In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the “Prognostic miRNA Database” indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p).Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker. Keywords: GBM, miRNA, temozolomide |
first_indexed | 2024-12-12T18:40:17Z |
format | Article |
id | doaj.art-7362bc54b37f4aadb1a5de236436990f |
institution | Directory Open Access Journal |
issn | 2162-2531 |
language | English |
last_indexed | 2024-12-12T18:40:17Z |
publishDate | 2018-12-01 |
publisher | Elsevier |
record_format | Article |
series | Molecular Therapy: Nucleic Acids |
spelling | doaj.art-7362bc54b37f4aadb1a5de236436990f2022-12-22T00:15:41ZengElsevierMolecular Therapy: Nucleic Acids2162-25312018-12-0113642650miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating BiomarkerArulraj Nadaradjane0Joséphine Briand1Gwenola Bougras-Cartron2Valentine Disdero3François M. Vallette4Jean-Sébastien Frenel5Pierre-François Cartron6Equipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest site René Gauducheau, Saint Herblain, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, France; LabEX IGO, Université de Nantes, Nantes, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest site René Gauducheau, Saint Herblain, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, France; LabEX IGO, Université de Nantes, Nantes, France; Corresponding author: Pierre-François Cartron, Equipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France.In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the “Prognostic miRNA Database” indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p).Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker. Keywords: GBM, miRNA, temozolomidehttp://www.sciencedirect.com/science/article/pii/S2162253118302518 |
spellingShingle | Arulraj Nadaradjane Joséphine Briand Gwenola Bougras-Cartron Valentine Disdero François M. Vallette Jean-Sébastien Frenel Pierre-François Cartron miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker Molecular Therapy: Nucleic Acids |
title | miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker |
title_full | miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker |
title_fullStr | miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker |
title_full_unstemmed | miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker |
title_short | miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker |
title_sort | mir 370 3p is a therapeutic tool in anti glioblastoma therapy but is not an intratumoral or cell free circulating biomarker |
url | http://www.sciencedirect.com/science/article/pii/S2162253118302518 |
work_keys_str_mv | AT arulrajnadaradjane mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT josephinebriand mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT gwenolabougrascartron mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT valentinedisdero mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT francoismvallette mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT jeansebastienfrenel mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker AT pierrefrancoiscartron mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker |